Scholarlink

Purpose <p>Cachexia is a prominent contributor to morbidity and mortality in the cancer, kidney disease and chronic heart failure. Therefore, the aim of the study was to assess the therapeutic effects of the soya phosphatidylcholine (SPC) in experimentally induced cachexia.</p> Methods <p>Cachexia was induced by administration of cisplatin (2&#xa0;mg/kg, i.p.) twice weekly for three weeks. Treatment of SPC (100, 200, 400&#xa0;mg/kg/d, p.o.) and megestrol (10&#xa0;mg/kg/d, i.p.) commenced from day 1 and continued for four weeks. At the end of experiment, various parameters including % reduction in body weight and body mass index (BMI), gastrocnemius muscle weight, carcass weight, carcass protein and fat content were measured. Further, C-reactive protein (CRP), IL-6 and TNF-α in serum while antioxidant enzymes (SOD, catalase, reduced glutathione) in homogenate of gastrocnemius muscle were measured.</p> Results <p>The SPC and megestrol treatments significantly prevented the loss of body weight and BMI as compared to the disease control (DC). Gastrocnemius muscle weight significantly higher in SPC and megestrol treated group compared to DC. The SPC (400&#xa0;mg/kg) significantly increased the carcass weight, carcass protein and fat content compared to DC. Similarly, the SPC (400&#xa0;mg/kg) significantly reduced CRP, IL-6, and TNF-α levels and markedly elevated all antioxidant enzyme levels in the gastrocnemius muscle homogenate as compared to DC.</p> Conclusion <p>In the present investigation, the SPC treatment showed the beneficial effects in experimentally induced cachexia. This effect might be due to anti-inflammatory and antioxidant potential of SPC. However, further investigations are required to elucidate precise underlying mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic potential of soy phosphatidylcholine in experimentally induced cachexia: Targeting antioxidant and inflammatory pathway

  • 期刊论文

  • 发表日期：

    2025年12月29日

查看全文
  • Aastha Bhavsar,
  • Chirag Patel,
  • Sandip Patel,
  • Devang Sheth,
  • Sandip Dholakia,
  • Jayesh V. Beladiya

摘要

Purpose

Cachexia is a prominent contributor to morbidity and mortality in the cancer, kidney disease and chronic heart failure. Therefore, the aim of the study was to assess the therapeutic effects of the soya phosphatidylcholine (SPC) in experimentally induced cachexia.

Methods

Cachexia was induced by administration of cisplatin (2 mg/kg, i.p.) twice weekly for three weeks. Treatment of SPC (100, 200, 400 mg/kg/d, p.o.) and megestrol (10 mg/kg/d, i.p.) commenced from day 1 and continued for four weeks. At the end of experiment, various parameters including % reduction in body weight and body mass index (BMI), gastrocnemius muscle weight, carcass weight, carcass protein and fat content were measured. Further, C-reactive protein (CRP), IL-6 and TNF-α in serum while antioxidant enzymes (SOD, catalase, reduced glutathione) in homogenate of gastrocnemius muscle were measured.

Results

The SPC and megestrol treatments significantly prevented the loss of body weight and BMI as compared to the disease control (DC). Gastrocnemius muscle weight significantly higher in SPC and megestrol treated group compared to DC. The SPC (400 mg/kg) significantly increased the carcass weight, carcass protein and fat content compared to DC. Similarly, the SPC (400 mg/kg) significantly reduced CRP, IL-6, and TNF-α levels and markedly elevated all antioxidant enzyme levels in the gastrocnemius muscle homogenate as compared to DC.

Conclusion

In the present investigation, the SPC treatment showed the beneficial effects in experimentally induced cachexia. This effect might be due to anti-inflammatory and antioxidant potential of SPC. However, further investigations are required to elucidate precise underlying mechanisms.